NZ331490A - Pyrrolopyrrolone derivatives for the treatment or prophylaxis of inflammatory disease such as chronic bronchitis, obstructive pulmonary disease and asthma - Google Patents

Pyrrolopyrrolone derivatives for the treatment or prophylaxis of inflammatory disease such as chronic bronchitis, obstructive pulmonary disease and asthma

Info

Publication number
NZ331490A
NZ331490A NZ331490A NZ33149097A NZ331490A NZ 331490 A NZ331490 A NZ 331490A NZ 331490 A NZ331490 A NZ 331490A NZ 33149097 A NZ33149097 A NZ 33149097A NZ 331490 A NZ331490 A NZ 331490A
Authority
NZ
New Zealand
Prior art keywords
hexahydro
rel
pyrrol
pyrrolo
compound
Prior art date
Application number
NZ331490A
Other languages
English (en)
Inventor
Michael Dennis Dowle
Harry Finch
Lee Andrew Harrison
Graham George Adam Inglis
Martin Redpath Johnson
Simon John Fawcett Macdonald
Pritom Shah
Robin Andrew Smith
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606508.1A external-priority patent/GB9606508D0/en
Priority claimed from GBGB9623001.6A external-priority patent/GB9623001D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NZ331490A publication Critical patent/NZ331490A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
NZ331490A 1996-03-28 1997-03-26 Pyrrolopyrrolone derivatives for the treatment or prophylaxis of inflammatory disease such as chronic bronchitis, obstructive pulmonary disease and asthma NZ331490A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9606508.1A GB9606508D0 (en) 1996-03-28 1996-03-28 Chemical componds
GBGB9623001.6A GB9623001D0 (en) 1996-11-05 1996-11-05 Chemical compounds
PCT/EP1997/001530 WO1997036903A1 (en) 1996-03-28 1997-03-26 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase

Publications (1)

Publication Number Publication Date
NZ331490A true NZ331490A (en) 2000-06-23

Family

ID=26309008

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ331490A NZ331490A (en) 1996-03-28 1997-03-26 Pyrrolopyrrolone derivatives for the treatment or prophylaxis of inflammatory disease such as chronic bronchitis, obstructive pulmonary disease and asthma

Country Status (30)

Country Link
US (3) US5994344A (enExample)
EP (1) EP0891362B1 (enExample)
JP (1) JP4118337B2 (enExample)
KR (1) KR20000005039A (enExample)
CN (1) CN1067075C (enExample)
AP (1) AP823A (enExample)
AR (1) AR006401A1 (enExample)
AT (1) ATE261969T1 (enExample)
AU (1) AU726649B2 (enExample)
BR (1) BR9708449A (enExample)
CA (1) CA2250209A1 (enExample)
CO (1) CO4790152A1 (enExample)
CZ (1) CZ309798A3 (enExample)
DE (1) DE69728139T2 (enExample)
DK (1) DK0891362T3 (enExample)
EA (1) EA001437B1 (enExample)
EE (1) EE9800335A (enExample)
ES (1) ES2217404T3 (enExample)
HU (1) HUP9900567A3 (enExample)
IL (1) IL125859A0 (enExample)
IS (1) IS4837A (enExample)
NO (1) NO984470L (enExample)
NZ (1) NZ331490A (enExample)
PE (1) PE55298A1 (enExample)
PL (1) PL329153A1 (enExample)
PT (1) PT891362E (enExample)
SK (1) SK132498A3 (enExample)
TR (1) TR199801935T2 (enExample)
WO (1) WO1997036903A1 (enExample)
YU (1) YU41198A (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9719189D0 (en) * 1997-09-09 1997-11-12 Glaxo Group Ltd New therapeutic method
GB9719187D0 (en) 1997-09-09 1997-11-12 Glaxo Group Ltd Compounds
PE107899A1 (es) * 1997-09-09 1999-11-17 Glaxo Group Ltd Derivados de pirrolopirrolona como inhibidores de elastasa leucocitaria
GB9719172D0 (en) 1997-09-09 1997-11-12 Glaxo Group Ltd Compounds
GB9821199D0 (en) * 1998-09-30 1998-11-25 Glaxo Group Ltd Chemical compounds
GB9905418D0 (en) * 1999-03-09 1999-05-05 Glaxo Group Ltd Process
AU2003216707A1 (en) * 2003-03-10 2004-09-30 Hetero Drugs Limited Amorphous clopidogrel hydrogen sulfate
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
AU2007351866C1 (en) * 2003-06-20 2013-07-25 Siga Technologies, Inc. Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US7692037B2 (en) * 2004-09-02 2010-04-06 Eastman Chemical Company Optimized liquid-phase oxidation
GB2418427A (en) 2004-09-02 2006-03-29 Univ Cambridge Tech Ligands for G-protein coupled receptors
AU2005283326B2 (en) * 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
GB0512238D0 (en) * 2005-06-15 2005-07-27 Univ Cambridge Tech Anti-inflammatory agents
RU2008140144A (ru) 2006-03-10 2010-04-20 Оно Фармасьютикал Ко., Лтд. (Jp) Азотосодержащее гетероциклическое производное и фармацевтическое средство, включающее такое производное в качестве активного ингредиента
EP2231600B1 (en) 2007-11-16 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
EP2231666B1 (en) 2007-12-12 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
WO2009132136A1 (en) 2008-04-23 2009-10-29 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
GEP20186885B (en) * 2012-12-18 2018-08-10 Chiesi Farma Spa Novel compounds
AU2020349353A1 (en) 2019-09-17 2022-04-14 Duke University Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
HUE064089T2 (hu) 2020-04-16 2024-02-28 Mereo Biopharma 4 Ltd Alvelesztat neutrofil elasztáz inhibitort alkalmazó módszerek alfa-1-antitripszin hiány által közvetített légzõszervi megbetegedés kezelésére
AU2022373971A1 (en) 2021-10-20 2024-04-04 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2932650A (en) * 1957-11-19 1960-04-12 Arthur C Cope 2-6-diazabicyclo (3. 3. 0) octanes
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
GB9211783D0 (en) * 1992-06-04 1992-07-15 Ici Plc Amide derivatives
GB9402680D0 (en) * 1994-02-11 1994-04-06 Zeneca Ltd Pyrrolidine derivatives
US5610296A (en) * 1994-12-05 1997-03-11 G. D. Searle & Co. Process for the preparation of amidino phenyl pyrrolidine beta-alanine urea analogs

Also Published As

Publication number Publication date
IS4837A (is) 1998-08-28
NO984470D0 (no) 1998-09-25
US5994344A (en) 1999-11-30
DK0891362T3 (da) 2004-07-12
EA199800773A1 (ru) 1999-06-24
WO1997036903A1 (en) 1997-10-09
JP4118337B2 (ja) 2008-07-16
IL125859A0 (en) 1999-04-11
PE55298A1 (es) 1998-09-19
HUP9900567A3 (en) 2001-02-28
ATE261969T1 (de) 2004-04-15
EP0891362B1 (en) 2004-03-17
AP823A (en) 2000-04-25
EA001437B1 (ru) 2001-02-26
BR9708449A (pt) 1999-08-03
JP2000507950A (ja) 2000-06-27
NO984470L (no) 1998-11-25
US6057457A (en) 2000-05-02
CO4790152A1 (es) 1999-05-31
CA2250209A1 (en) 1997-10-09
YU41198A (sh) 1999-09-27
SK132498A3 (en) 1999-08-06
EP0891362A1 (en) 1999-01-20
AU2291797A (en) 1997-10-22
DE69728139T2 (de) 2004-10-21
EE9800335A (et) 1999-04-15
CZ309798A3 (cs) 1999-02-17
AU726649B2 (en) 2000-11-16
DE69728139D1 (de) 2004-04-22
CN1219935A (zh) 1999-06-16
CN1067075C (zh) 2001-06-13
PT891362E (pt) 2004-08-31
ES2217404T3 (es) 2004-11-01
PL329153A1 (en) 1999-03-15
KR20000005039A (ko) 2000-01-25
AR006401A1 (es) 1999-08-25
HUP9900567A2 (hu) 1999-06-28
AP9801351A0 (en) 1998-09-30
TR199801935T2 (xx) 1999-03-22
US6215002B1 (en) 2001-04-10

Similar Documents

Publication Publication Date Title
EP0891362B1 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
EP0303697B1 (en) Derivatives of physiologically active substance k-252
CN101305011B (zh) 吡啶衍生物及其在治疗精神障碍中的用途
CA2978170C (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
AU2010294292B2 (en) Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer
AU2004247487B2 (en) N-pyrrolidin-3-YL-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
TW201602084A (zh) 纖維母細胞生長因子受體抑制劑
JP2003523344A (ja) ピロロピリミジノン誘導体とその製造方法、およびその用途
MX2012004379A (es) Compuestos de pirrolo[2,3-d]pirimidina.
MX2010013773A (es) Compuestos de 2,4'-bipiridinilo como inhibidores de cinasa d de proteina utiles para el tratamiento de, entre otras, insuficiencia cardiaca ia y cancer.
TW201605859A (zh) 作為酪蛋白激酶1δ/ε抑制劑之新穎經取代之吡唑并-哌
CN114502533A (zh) 苯磺酰胺衍生物及其用途
CN111433207A (zh) 作为αV整合素抑制剂的吡咯并吡嗪衍生物
KR20170032420A (ko) Pde 억제제로서의 신규한 2,5-치환된 피리미딘
AU9741298A (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
KR101216965B1 (ko) 아미노아세틸피롤리딘카르보니트릴 유도체의 제조방법 및 그 제조 중간체
AU9536098A (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
WO1999012934A1 (en) Pyrrolopyrrolone derivatives
WO2016164754A1 (en) Fgfr4 inhibitors
HK40089371A (en) Macrocyclic diamine derivatives as ent inhibitors for the treatment of cancers, and combination thereof with adenosine receptor antagonists
JPWO1988007045A1 (ja) 生理活性物質k‐252の誘導体
CZ2000878A3 (cs) Pyrrolopyrrolonové deriváty